Episode Details

In this solo episode, David Brühlmann explores the evolving landscape of biologic manufacturing platforms beyond CHO (Chinese hamster ovary) cells. Drawing from previous interviews with platform pioneers and rigorous data analysis, David examines where established and emerging hosts find their strengths—and their limits—in today’s biomanufacturing environment.

Topics Discussed

• The historical dominance of CHO cells and what’s changed in the last decade (00:08)
• Three critical areas where alternative hosts might outperform CHO: cost, speed, and intrinsic product quality (04:52)
• Moss as a production platform: regulatory advantages, glycosylation, and oncology antibodies (05:47)
• Microalgae’s carbon-negative potential and the current 1000-fold yield challenge (08:28)
• Molecular farming (plant-based production): timelines, case of the Medicago COVID-19 vaccine, and overcoming political—not technical—barriers (10:41)
• Silkworm-based production: infrastructure cost, individual variability, and progress in vaccines (13:07)
• Cyanobacteria: promise of photosynthetic biomanufacturing and current limitations for clinical use (15:06)
• The pattern emerging among all alternative platforms: finding niche advantages rather than universally replacing CHO (18:25)
• A framework for evaluating novel hosts moving forward (19:14)

Part 2 examines whether “Will it replace CHO?” is the right question to be asking at all, and introduces an alternative framework for evaluating the issue more effectively.

Smart insight:

None of the “novel hosts” are universal CHO replacements. Winners emerge in narrow niches: plant farming for pandemic-scale vaccines, silkworms in veterinary and oral applications, and cyanobacteria as a long-term bet for sustainable production.

Here are the episodes referenced:

• Episodes 163 - 164: How Moss Enables Production of Unproducible Protein Therapeutics with Andreas Schaaf
• Episodes 141 - 142: How Microalgae Cuts Antibody Costs by 70% and Redefines Biomanufacturing with Muriel Bardor
• Episodes 235 - 236: Plant-Based Biomanufacturing: How Molecular Farming Produces Biopharmaceuticals in Weeks, Not Months with Waranyoo Phoolcharoen
• Episodes 217 - 218: Silkworm Biomanufacturing: From Ancient Silk Production to Phase I Vaccine Trials with Masafumi Osawa
• Episodes 229 - 230: Cyanobacteria Biomanufacturing: Achieving Carbon-Neutral Production at Lower Cost Than Fermentation with Tim Corcoran

Next:

If you enjoyed this episode, please leave a review on Apple Podcasts or your favorite podcast platform. By doing so, we can empower more scientists like you. Stay tuned for more inspiring biotech insights in our next episode.

Support the show